within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD12_PioglitazoneAndSitagliptin;

model PioglitazoneAndSitagliptin
  extends Pharmacolibrary.Drugs.ATC.A.A10BD12;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A10BD12</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Pioglitazone and sitagliptin is a fixed-dose combination of an oral antidiabetic thiazolidinedione (pioglitazone) and a dipeptidyl peptidase-4 (DPP-4) inhibitor (sitagliptin) used in the management of type 2 diabetes mellitus. Pioglitazone increases insulin sensitivity, while sitagliptin enhances incretin hormone levels, leading to improved glycemic control. This combination is approved in several countries for use as part of a comprehensive diabetes treatment regimen.</p><h4>Pharmacokinetics</h4><p>Estimated composite pharmacokinetic parameters for healthy adult subjects, based on published data for individual drugs (pioglitazone and sitagliptin), as no specific published population pharmacokinetic models for the fixed-dose combination were located.</p><h4>References</h4><ol><li><p>Lyseng-Williamson, KA (2007). Sitagliptin. <i>Drugs</i> 67(4) 587–597. DOI:<a href=\"https://doi.org/10.2165/00003495-200767040-00007\">10.2165/00003495-200767040-00007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17352516/\">https://pubmed.ncbi.nlm.nih.gov/17352516</a></p></li><li><p>Burness, CB, &amp; Scott, LJ (2015). Dulaglutide: A Review in Type 2 Diabetes. <i>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</i> 29(6) 407–418. DOI:<a href=\"https://doi.org/10.1007/s40259-015-0143-4\">10.1007/s40259-015-0143-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26423061/\">https://pubmed.ncbi.nlm.nih.gov/26423061</a></p></li><li><p>Kadokura, T, et al., &amp; Smulders, R (2014). Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. <i>Clinical pharmacokinetics</i> 53(11) 975–988. DOI:<a href=\"https://doi.org/10.1007/s40262-014-0180-z\">10.1007/s40262-014-0180-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25316572/\">https://pubmed.ncbi.nlm.nih.gov/25316572</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end PioglitazoneAndSitagliptin;
